What to Expect Week by Week on Semaglutide: A Complete Timeline
A detailed week-by-week and month-by-month timeline of what to expect on semaglutide, from your first injection through year two and beyond. Covers appetite changes, weight loss milestones, side effects, and dose escalation.
More on Getting Started with GLP-1
Why a Week-by-Week Timeline Matters
Starting semaglutide is one of the most significant decisions you can make for your metabolic health. Whether you have been prescribed Ozempic for type 2 diabetes or Wegovy for chronic weight management, understanding what lies ahead — week by week, month by month — is essential for setting realistic expectations, staying motivated through challenging periods, and recognizing when something is or is not progressing normally. The clinical trials that established semaglutide as a groundbreaking obesity treatment enrolled thousands of participants and tracked outcomes over 68 weeks, giving us a remarkably detailed picture of what the typical patient journey looks like.
What the clinical trial data does not always capture, however, is the lived experience of each phase — the subtle appetite changes in week one, the frustration when the scale does not move during the adjustment period, the exhilaration of seeing meaningful weight loss accelerate during month three, and the psychological adjustment that comes with maintaining a significantly lower body weight over the long term. This guide synthesizes clinical evidence with real-world patient experience to give you the most complete possible picture of your semaglutide journey.
One critical point before we begin: every patient's timeline is different. The week-by-week milestones described below represent averages and typical experiences. Some patients lose weight faster, some slower. Some experience significant side effects, others almost none. Your individual response depends on your starting weight, metabolic health, genetics, diet, physical activity level, and numerous other factors. Use this guide as a general roadmap, not a rigid prescription. Your healthcare provider is the best source of personalized guidance throughout your treatment.
Dose Escalation Schedule
Semaglutide (Wegovy) follows a standard 16-week dose escalation: 0.25 mg (weeks 1–4), 0.5 mg (weeks 5–8), 1.0 mg (weeks 9–12), 1.7 mg (weeks 13–16), and 2.4 mg (week 17 onward). Your provider may adjust this timeline based on your individual response and tolerability.
Weeks 1–2: The Beginning (0.25 mg)
Your semaglutide journey begins with the lowest dose: 0.25 mg injected once weekly. This dose is intentionally sub-therapeutic for weight loss — its primary purpose is to give your gastrointestinal system time to adjust to the presence of a GLP-1 receptor agonist. During the first week, many patients report their first injection experience as surprisingly uneventful. The injection itself is quick and nearly painless with the modern autoinjector pens, and the medication begins working within hours as it binds to GLP-1 receptors throughout your body.
By day two or three after your first injection, you may begin noticing the earliest appetite changes. These are often subtle — a slight decrease in interest in food, feeling satisfied sooner during meals, or noticing that the mid-afternoon snack urge is less compelling than usual. Not everyone notices these changes immediately, and their absence does not indicate the medication is not working. GLP-1 receptors are being activated and the downstream signaling cascades are beginning, even if the subjective experience has not yet shifted.
The most common side effect during weeks 1–2 is mild nausea. In clinical trials, approximately 20% of patients experienced some degree of nausea during the initial dosing period. This nausea is typically mild, intermittent, and most pronounced in the 24–48 hours after injection. It tends to improve as the week progresses and the medication reaches a steady state. Other early side effects may include mild constipation, slight fatigue, or a general sense of abdominal fullness. Severe side effects at this dose are uncommon. If you experience persistent vomiting, severe abdominal pain, or signs of dehydration, contact your provider immediately. For strategies on managing early nausea, see our guide on how to stop nausea on semaglutide.
First appetite changes may appear within 2–3 days of your first injection
Mild nausea affects approximately 20% of patients and usually resolves within days
Weight loss at this stage is minimal — focus is on building medication tolerance
The injection is quick and nearly painless with modern autoinjector pens
Weeks 3–4: Early Adjustment (0.25 mg)
By weeks 3–4, your body has had two to three additional exposures to semaglutide at the 0.25 mg dose, and the GLP-1 receptor activation is reaching a more consistent steady state. Most patients who experienced early nausea find it has largely resolved or become significantly milder by this point. The appetite suppression effect, if it was subtle in weeks 1–2, often becomes more noticeable now. Patients frequently describe a shift in their relationship with food — cravings for calorie-dense foods may diminish, portion sizes naturally decrease, and the compulsive or emotional eating patterns that many patients have struggled with for years begin to loosen their grip.
Weight loss during weeks 3–4 is typically modest: most patients have lost between 1% and 3% of their starting body weight by the end of the first month. For a 220-pound patient, that translates to roughly 2–7 pounds. Some patients see more on the scale due to early water weight changes, while others see less. Both outcomes are entirely normal and not predictive of long-term success. The STEP 1 clinical trial data shows that patients who had modest first-month results went on to achieve the same overall weight loss percentages as those with faster early starts.
This is also the period where establishing good habits around your injection routine becomes important. Choosing a consistent day of the week, rotating injection sites properly, and learning to inject semaglutide correctly all contribute to a smoother long-term experience. Many patients also begin making dietary adjustments during this period — not because the medication forces them to, but because reduced appetite creates a natural opportunity to choose more nutrient-dense foods.
Month 2: First Dose Increase (0.5 mg)
At week 5, your provider will increase your semaglutide dose to 0.5 mg. This is the first dose escalation, and it is a pivotal moment in treatment. The doubling of the dose produces a noticeable increase in GLP-1 receptor activation, and most patients experience a clear intensification of the appetite-suppressing effect. Meals that felt adequately small at 0.25 mg may now feel too large. The feeling of satiety after eating arrives earlier and lasts longer. Food noise — that persistent background mental chatter about food and eating that many patients with obesity describe — often quiets significantly at this dose.
The dose increase will likely trigger a temporary return of gastrointestinal side effects, though typically milder than the initial experience. Nausea may reappear for 3–5 days, and some patients notice increased constipation or mild diarrhea. These symptoms generally resolve faster than they did during the initial adjustment because your body has already begun adapting to GLP-1 receptor activation. Eating smaller, more frequent meals and avoiding high-fat foods can help manage the transition. For a complete understanding of the dosing schedule, visit our semaglutide dosage guide.
Weight loss typically begins accelerating during month 2. By the end of week 8, most patients have lost 3–5% of their starting body weight. This is where many patients begin to feel genuinely encouraged — the scale is moving consistently, clothes are fitting differently, and the medication is clearly producing measurable results. It is also a period where the psychological impact of weight loss begins to emerge. Patients report improved mood, increased energy, and greater confidence in their ability to maintain long-term changes.
Month 2 Milestone
The 0.5 mg dose often marks the transition from "adjustment phase" to "active weight loss phase." Most patients notice a clear intensification of appetite suppression and begin seeing consistent weekly weight loss of 0.5–1.5 pounds.
Month 3: Building Momentum (1.0 mg)
The dose escalation to 1.0 mg at week 9 often represents a turning point for many patients. At this dose, semaglutide's full pharmacological profile becomes more apparent. Appetite suppression is typically robust and consistent. Gastric emptying is meaningfully slowed, which means meals stay in the stomach longer and the feeling of fullness persists. Many patients find that they naturally adopt a pattern of smaller, more frequent meals because large portions become genuinely uncomfortable.
By the end of month 3, the typical patient has lost 5–7% of their starting body weight. For a 220-pound individual, this represents 11–15 pounds — a clinically meaningful reduction that is beginning to produce measurable health improvements. Blood pressure often shows early improvements, fasting glucose levels may begin declining in patients with prediabetes or type 2 diabetes, and inflammatory markers start trending downward. These metabolic improvements are occurring alongside the visible changes on the scale and in the mirror.
The 1.0 mg dose is where some patients begin to encounter the question of whether they need to continue escalating. A subset of patients achieves excellent appetite control and meaningful weight loss at 1.0 mg and their providers may choose to maintain this dose rather than pushing higher. This is a legitimate clinical strategy — the goal is to find the minimum effective dose that produces satisfactory results with acceptable side effects. Discuss with your provider whether continued escalation is appropriate for your individual situation. Understanding your expected semaglutide weight loss results can help frame these conversations productively.
Months 4–6: The Optimization Phase (1.7 mg to 2.4 mg)
Months 4 through 6 represent the peak weight loss velocity phase for most semaglutide patients. During this window, the dose reaches the therapeutic target range (1.7 mg at week 13 and the full 2.4 mg at week 17 for Wegovy), and the body's metabolic adaptation to the medication is well established. Weekly weight loss during this phase is typically in the range of 1–2 pounds per week, though individual variation is significant. Patients who are simultaneously incorporating regular physical activity and making dietary improvements often see results at the higher end of this range.
By the end of month 6, the average patient has lost 10–12% of their starting body weight. This is a landmark milestone — a 10% reduction in body weight is associated with clinically significant improvements in nearly every obesity-related comorbidity, including type 2 diabetes, hypertension, obstructive sleep apnea, nonalcoholic fatty liver disease, and osteoarthritis. Many patients find that their medication dosages for blood pressure, cholesterol, or blood sugar can be reduced during this phase as their metabolic health improves.
Side effects during months 4–6 have typically stabilized for most patients. Those who experienced significant early GI issues usually find that their body has adapted. However, a subset of patients does experience persistent nausea, constipation, or fatigue at the higher doses. If side effects remain problematic, your provider may consider a dose reduction or a slower escalation timeline. The complete semaglutide side effects guide details management strategies for persistent symptoms. Additionally, patients who have not yet developed a regular exercise routine should consider starting one during this phase, as physical activity helps preserve lean muscle mass during weight loss and improves overall metabolic outcomes.
Peak weight loss velocity typically occurs during months 4–6
Average total body weight loss reaches 10–12% by the end of month 6
Clinically significant improvements in blood pressure, blood sugar, and cholesterol are common
Side effects generally stabilize, though dose adjustments may be needed for persistent symptoms
Physical activity becomes increasingly important for preserving muscle mass
Months 7–12: Approaching Maximum Benefit
During the second half of the first year, the rate of weight loss gradually decelerates, but the cumulative results continue to build. This deceleration is not a sign that the medication is failing — it is a natural physiological consequence of the body's metabolic adaptation to its new, lower weight. As you lose weight, your basal metabolic rate decreases because a smaller body requires fewer calories to maintain itself. The rate of weekly weight loss may slow from 1–2 pounds per week to 0.5–1 pound per week during this phase.
By the end of month 12, the average semaglutide patient has lost approximately 12–15% of their starting body weight. In the landmark STEP 1 trial, the average weight loss at 68 weeks (approximately 15.5 months) was 14.9% of body weight on the 2.4 mg dose. Some patients exceed 20% total body weight loss, placing them in the exceptional responder category. Others may plateau earlier at 8–10%, which is still a clinically meaningful outcome. Your first month on semaglutide may feel distant at this point, but reflecting on how far you have come can be a powerful motivator.
This period also marks an important psychological transition. The novelty of the medication has worn off, the rapid early weight loss has slowed, and the reality of long-term treatment becomes more concrete. Many patients experience a period of adjustment during months 8–12 where they need to recalibrate their expectations and recommit to the lifestyle factors — diet quality, physical activity, sleep, stress management — that work synergistically with the medication. Patients who view semaglutide as one component of a comprehensive metabolic health strategy tend to have the best long-term outcomes. Understanding the full range of available GLP-1 treatments can also help you and your provider make informed decisions about your ongoing care.
Year 2 and Beyond: Maintenance and Long-Term Success
For patients who continue semaglutide beyond the first year, the focus shifts from active weight loss to weight maintenance. The STEP 5 extension trial provided critically important data on long-term outcomes, showing that patients who remained on semaglutide through 104 weeks (2 years) maintained their weight loss, while those who discontinued the medication regained approximately two-thirds of the lost weight within one year. This finding underscores a key reality: for most patients, semaglutide is a long-term or indefinite medication, not a short-term intervention.
During the maintenance phase, some patients and providers explore dose optimization strategies. If a patient has achieved their weight loss goals and is experiencing bothersome side effects at the 2.4 mg dose, a trial reduction to 1.7 mg or even 1.0 mg may be considered. The goal is to find the minimum effective dose that maintains weight loss while minimizing side effects and cost. This requires careful monitoring — weight, appetite, metabolic markers — to ensure that a dose reduction does not lead to gradual weight regain. The question of what happens when you stop GLP-1 medication is one that every long-term patient should discuss with their provider.
Long-term safety data for semaglutide continues to accumulate. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients taking semaglutide for obesity, establishing a cardiovascular benefit that extends well beyond weight loss alone. Ongoing post-marketing surveillance continues to monitor for rare adverse events, and the overall safety profile remains favorable for the vast majority of patients. Regular follow-up with your prescribing provider — typically every 3–6 months once stable — is essential for monitoring your ongoing response and addressing any concerns.
Continue regular provider follow-up
Even after reaching your maintenance phase, regular check-ins every 3–6 months help monitor metabolic markers, medication response, and overall health trajectory.
Maintain physical activity
Exercise becomes even more important during maintenance to preserve muscle mass, support metabolic rate, and provide cardiovascular benefits independent of weight loss.
Focus on diet quality over restriction
During maintenance, shift your nutritional focus from caloric restriction toward nutrient density. Protein intake is especially important for maintaining lean body mass.
Monitor for dose adjustment opportunities
Some patients can successfully maintain their weight loss at a lower dose, reducing side effects and cost. Work with your provider to explore this possibility.
Common Challenges and How to Navigate Them
No semaglutide journey is without its challenges. Understanding the most common obstacles — and knowing that they are shared experiences, not personal failures — can help you navigate them more effectively. One of the most frequent challenges is the weight loss plateau, which typically occurs around months 6–9 for many patients. During a plateau, the scale may not move for 2–4 weeks despite continued adherence to the medication and healthy habits. Plateaus are a normal part of weight loss and do not necessarily indicate a problem with your treatment.
Another common challenge is managing social situations around food and alcohol while on semaglutide. Your appetite is significantly different from what it was before treatment, which can make dining out, attending parties, or sharing meals with family and friends feel awkward. Planning ahead, being open with trusted friends and family about your treatment, and focusing on the social rather than the culinary aspects of gatherings can help. For specific guidance on alcohol, read our article on GLP-1 and alcohol risks.
Fatigue and low energy are challenges that some patients face, particularly during the dose escalation phase. Because semaglutide significantly reduces caloric intake, some patients inadvertently consume too few calories, leading to fatigue, brain fog, and muscle weakness. Working with a registered dietitian to ensure adequate caloric and protein intake can help. Your Trimi care team can provide personalized nutritional guidance tailored to your treatment phase and goals. Understanding the importance of maintenance dosing also becomes relevant as you progress through treatment.
Frequently Asked Questions
How much weight will I lose in the first month on semaglutide?
Most patients lose between 1% and 3% of their starting body weight during the first month on semaglutide. For a person weighing 220 pounds, this translates to roughly 2–7 pounds. The first month is primarily an adjustment period at the lowest dose (0.25 mg), so the focus is on building tolerance rather than maximizing weight loss. Some patients see more dramatic early results due to reduced appetite and water weight changes, while others see minimal scale movement. Both are normal. The clinical trials showed that meaningful weight loss accelerates during months 2–4 as the dose increases.
When will I start feeling less hungry on semaglutide?
Appetite suppression typically begins within the first 1–2 weeks of starting semaglutide, even at the lowest 0.25 mg dose. Many patients describe a sudden realization that they forgot to eat lunch or that they feel full after a few bites of a meal. However, this effect varies considerably between individuals. Some patients notice appetite changes within days of their first injection, while others do not experience significant appetite reduction until reaching a higher dose (0.5 mg or 1 mg). The appetite suppression effect generally strengthens with each dose increase and tends to stabilize once a patient reaches their maintenance dose.
What are the worst weeks for side effects on semaglutide?
Side effects tend to be most pronounced during two specific windows: the first 1–2 weeks after starting semaglutide (weeks 1–2 overall) and the first 1–2 weeks after each dose escalation. This means weeks 1–2, weeks 5–6 (after the increase to 0.5 mg), weeks 9–10 (after 1.0 mg), weeks 13–14 (after 1.7 mg), and weeks 17–18 (after reaching 2.4 mg) are common periods of increased nausea and GI symptoms. Most patients find that side effects diminish significantly within 5–7 days of each adjustment. Eating smaller meals, staying hydrated, and following your provider's dietary guidance can help manage these transition periods.
Is it normal to not lose weight in the first few weeks on semaglutide?
Yes, it is completely normal and not a cause for concern. The first four weeks on semaglutide are designed as an adjustment period at the lowest therapeutic dose (0.25 mg). This dose is intentionally sub-therapeutic for weight loss — its purpose is to help your body acclimate to the medication and minimize gastrointestinal side effects. Some patients see no scale change or even a slight increase during this period due to water retention, hormonal fluctuations, or other factors. Clinical trial data shows that the most significant weight loss occurs between months 3 and 12, so patience during the early phase is important.
How long does it take to reach the full dose of semaglutide?
The standard dose escalation schedule for semaglutide (Wegovy) takes 16 weeks to reach the target maintenance dose of 2.4 mg. The schedule is: weeks 1–4 at 0.25 mg, weeks 5–8 at 0.5 mg, weeks 9–12 at 1.0 mg, weeks 13–16 at 1.7 mg, and then 2.4 mg from week 17 onward. Some providers may modify this timeline based on individual tolerance. If side effects are severe at a particular dose, your provider may extend the time at that dose before escalating. Not all patients need to reach 2.4 mg — some achieve excellent results at lower doses, and the goal is to find the minimum effective dose with acceptable tolerability.
When does semaglutide weight loss plateau?
Most patients on semaglutide experience their maximum rate of weight loss between months 3 and 8, after which the rate begins to slow. Weight loss typically plateaus around months 12–16 for most patients, at which point they have achieved roughly 80–90% of their total expected weight loss. In the STEP 1 trial, the average total body weight loss at 68 weeks was approximately 14.9%. Some patients continue to see modest additional weight loss through month 18–20. A plateau does not mean the medication has stopped working — it means you have reached a new metabolic equilibrium where your reduced caloric intake matches your lower energy expenditure at your new weight.
What happens if I miss a week of semaglutide?
If you miss your scheduled weekly injection of semaglutide and it has been fewer than 5 days since your missed dose, take the injection as soon as you remember. If more than 5 days have passed, skip the missed dose and take your next injection on your regularly scheduled day. Do not double up on doses. A single missed dose is unlikely to significantly impact your overall progress, though some patients report a temporary return of appetite and cravings. If you miss multiple consecutive doses, contact your prescribing provider — you may need to restart at a lower dose to avoid severe gastrointestinal side effects when resuming.
Sources & References
- Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." NEJM, 2021;384:989–1002.
- Garvey WT, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." Nature Medicine, 2022;28:2083–2091.
- Lincoff AM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)." NEJM, 2023;389:2221–2232.
- Novo Nordisk. Wegovy (semaglutide) Prescribing Information. 2024.
- Rubino D, et al. "Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance." JAMA, 2021;325(14):1414–1425.
- Davies M, et al. "Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 2)." Lancet, 2021;397(10278):971–984.
- Wadden TA, et al. "Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy (STEP 3)." JAMA, 2021;325(14):1403–1413.
- Holst JJ. "The physiology of glucagon-like peptide 1." Physiological Reviews, 2007;87(4):1409–1439.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.